First, let’s get one thing straight. There is no “crisis.”
Now that Novartis, GlaxoSmithKline, AstraZeneca, Merck, and Sanofi have either scaled back or (in the case of GSK and AZ) abandoned any further Central Nervous System (CNS) R&D, the hand-wringing has begun, with distinguished professors like Dr. Steven E. Hyman writing alarmist editorials about the imperiled future of psych meds and articles in the media talking of a “crisis” in psych-med research. (The opening sentence of a recent editorial in Schizophrenia Bulletin was: “Psychopharmacology is in crisis.” The headline of Dr. Hyman’s piece is “Psychiatric Drug Development: Diagnosing a Crisis.”)
First, let’s get one thing straight. There is no “crisis.” A review of the new-drug pipeline shows that 137 active R&D programs have 417 ongoing development projects aimed at 19 psychiatric indications. Most of these programs are in Phase I or II trials. Psych-med R&D is more vigorous than ever.
The widely reported shutdown of CNS research programs at GSK and AZ (and the scale-backs at Pfizer and elsewhere) represent the continuation of a process begun long ago, to outsource riskier types of development to academia (which gets funding from the drug companies as well as government, via NIH and NMIH) and to smaller, less risk-averse drug companies (including startups) who eventually sell their projects back to the giant pharmas, once it looks like they’ve “got something.”
But the whole notion that a GSK or an AstraZeneca can convert R&D dollars into brand-new, never-tried-before, fundamentally innovative psych meds is ridiculous in the first place, because that’s not how development of new treatments works. You can only develop a targeted drug when you know the precise biochemical mechanism of action of the underlying disease. That’s not the case for depression, schizophrenia, or any of the other major psychiatric illnesses. As H. Christian Fibiger correctly points out in his Schizophrenia Bulletin piece:
The discovery of all three major classes of psychiatric drugs, antidepressants, antipsychotics, and anxiolytics, came about on the basis of serendipitous clinical observation. At the time of their discoveries, the mechanisms by which these molecules produce their effects were unknown, and it was only later that antipsychotics were shown to be D2 receptor antagonists, antidepressants monoamine reuptake inhibitors, and anxiolytics GABA receptor modulators. It is interesting and perhaps instructive to consider whether any of these classes of drugs could have been discovered by current drug discovery strategies. For example, what genetic or preclinical data exist that point to the D2 dopamine receptor as a likely target for antipsychotic activity? Presently there are no genetic data that suggest that this receptor is expressed or functions abnormally in psychotic disorders. And without the benefit of the prior clinical validation, it is difficult to see how preclinical data alone would point to the D2 receptor as an interesting potential target for the treatment of psychotic disorders. The same can be said for monoamine transporters with respect to depression where, like psychosis, there are no animal models based on disease pathophysiology and no compelling preclinical data pointing to these as potential targets for antidepressant drugs.
The best Big Pharma has been able to do over the years is craft me-too drugs once a serendipitous discovery has been made. But the serendipitous discoveries themselves (such as John Cade‘s discovery that injecting Guinea pigs with lithium urate made them placid) can’t be manufactured; they can’t be bought. They happen by accident.
The Latest Bing News on:
Psychiatric Drug Development
- Sociodemographic Factors May Predict Substance Use Initiation in Kidson May 7, 2024 at 2:14 pm
Sociodemographic factors such as religion and race were the most robust predictors of substance use initiation in early adolescence, according to an analysis of t ...
- Top Predictors of Substance Initiation in Youth Flaggedon May 7, 2024 at 12:18 pm
By age 12 years, 14% of children have started using alcohol or tobacco, with religion being one of the top predictors for substance use initiation.
- Study finds sociodemographic variables to be the most robust predictors of substance use initiationon May 7, 2024 at 9:17 am
New research, published online today in the Journal of Psychiatry, examined a broad range of potential predictors of substance use among adolescents and found sociodemographic variables were the most ...
- Dr. Richard Goldberg Joins Real Brands' Board of Directors, Enters Consulting Agreementon May 7, 2024 at 1:30 am
Goldberg has joined Real Brands Inc.'s Board of Directors and will consult for them on research and development of psychedelic drug therapies ... therapies for the treatment of an array of psychiatric ...
- Relevance of the Zimbabwe Drug and Substance Agency Billon May 4, 2024 at 8:07 pm
To ensure the realisation of our national vision 2030 the Cabinet has thus approved the Principles for the enactment of the Zimbabwe Drug and Substance Agency Bill, 2024 that paves way for the ...
- Study finds biomarkers for psychiatric symptoms in patients with rare genetic condition 22qon April 30, 2024 at 5:00 pm
A new UC Davis study finds biomarkers that could identify patients with 22q11.2 deletion syndrome who are more likely to develop psychosis.
- Men taking common hair loss drug ‘loved by Donald Trump’ warned of ‘psychiatric and sexual’ side effectson April 30, 2024 at 8:49 am
MEN who take the hair loss drug finasteride are being warned of psychiatric and sexual side effects. The medicine — taken by Donald Trump — can cause depression, suicidal thoughts, decreased ...
- Men on hair-loss drug warned of sexual and psychiatric side effectson April 29, 2024 at 1:01 pm
Men on a popular hair-loss drug have been warned of its potential serious sexual and psychiatric side effects by the drug regulator. The Medicines and Healthcare products Regulatory Agency (MHRA ...
- Men on hair-loss drug warned of sexual and psychiatric side effectson April 29, 2024 at 7:01 am
Men on a popular hair-loss drug have been warned of its potential serious sexual and psychiatric side effects by the drug regulator. The Medicines and Healthcare products Regulatory Agency (MHRA) said ...
- MDMA trials are showing it has promise as a psychiatric medicineon April 26, 2024 at 10:13 am
Such trials are already under way and are showing strong promise for both MDMA and psychedelics as effective psychiatric medicines ... cuts through both “war on drugs” scare stories and ...
The Latest Google Headlines on:
Psychiatric Drug Development
[google_news title=”” keyword=”Psychiatric Drug Development” num_posts=”10″ blurb_length=”0″ show_thumb=”left”] [/vc_column_text]The Latest Bing News on:
Drug research and development
- Google’s new AI model is ready to speed up drug development as we know iton May 8, 2024 at 8:16 pm
Google's AlphaFold 3 AI model revolutionizes drug discovery by predicting molecular structures for experts for free. Google's industry-focused AI projects include weather forecasting with GraphCast ...
- Regulatory Challenges In Drug Approval: Balancing Innovation And Patient Safetyon May 8, 2024 at 5:43 am
Navigating the complex landscape of drug approval presents significant regulatory challenges, requiring a delicate balance between fostering pharmaceutical innovation and ensuring patient safety. The ...
- Buy Rating Affirmed for Marinus Pharmaceuticals Amid Positive Sales and Promising Drug Trialson May 8, 2024 at 3:15 am
In a report released today, Jason Butler from JMP Securities reiterated a Buy rating on Marinus (MRNS – Research Report), with a price ... Pharmaceuticals’ consistent progress in its drug development ...
- Generative AI Finds Its Footing in Drug Developmenton May 7, 2024 at 9:06 pm
Since the 2022 launch of ChatGPT, biopharma has poured money into this new form of artificial intelligence, but companies remain cautious with unproven technology.
- Drug Delivery Collaboration, Development, Research and Licensing Deals Analysis Report 2024 with Directory of 1,666 Agreements Signed Since 2019on May 7, 2024 at 3:33 am
The "Drug Delivery Collaboration and Licensing Deals 2016-2024" report has been added tAndMarkets.com's offering.Drug Delivery Collaboration and Licensing Deals provides a comprehensive understanding ...
- Selvita completes acquisition of PozLab and significantly expands its drug development capabilitieson May 7, 2024 at 1:17 am
SLV] announced today completion of a strategic transaction in which it has acquired 100% of shares in PozLab. The closing of the transaction comes shortly after the announcement of the transaction on ...
- Buy Rating Affirmed for VYNE Therapeutics on Promising Drug Development Milestones and Positive Clinical Dataon May 6, 2024 at 7:15 am
H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on VYNE Therapeutics (VYNE – Research Report) today and set a price ...
- Bridging the gap between cancer drug target and cancer drugon May 2, 2024 at 8:43 am
Fred Hutch prostate cancer and RNA translation expert Dr. Andrew Hsieh was named a Harrington Discovery Institute 2024 Scholar-Innovator. The award will support Hsieh's efforts to turn a promising ...
- A Pharmaceutical Company is Working to Speed Up the Drug Development Process with AIon April 28, 2024 at 9:50 pm
Algorae Pharmaceuticals is finding ways to revamp its process of drug development from cost saving and speed to timeline of drug research and delivery by ...
- Kaposi sarcoma discovery could facilitate drug developmenton April 28, 2024 at 5:00 pm
Researchers have developed a model of Kaposi sarcoma that could expedite the development of new drugs to treat the disease, which is the most common cancer in people living with HIV.
The Latest Google Headlines on:
Drug research and development
[google_news title=”” keyword=”drug research and development” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]